Literature DB >> 17182752

Comparative study of Kaposi's sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis.

Maria Claudia Nascimento1, Vanda Akico de Souza, Laura Masami Sumita, Wilton Freire, Fernando Munoz, Joseph Kim, Claudio S Pannuti, Philippe Mayaud.   

Abstract

Accurate determination of infection with Kaposi's sarcoma-associated herpesvirus (KSHV) has been hindered by the lack of a "gold standard" for comparison of serological assays used to estimate KSHV prevalence in serosurveys conducted in different settings. We have evaluated the performance of five in-house (developed at University College London [UCL], United Kingdom, and at the virology laboratory of the Instituto de Medicine Tropical [IMT] in Sao Paulo, Brazil) and two commercial (ABI and DIAVIR) serological assays to detect antibodies to latency-associated nuclear antigen (LANA) and to lytic KSHV antigens. We used a variety of serum samples assembled to represent populations likely to be at high, intermediate, and low risk of KSHV infection in Brazil. Composite reference standard panels were prepared based on clinical and serological parameters, against which assay performances were assessed using conventional Bayesian statistics and latent class analysis (LCA). Against the clinical reference standard, in-house immunofluorescence assays to detect anti-LANA antibodies (IFA-LANA) produced at UCL and IMT had similar performances, with sensitivities of 61% (95% confidence interval [CI], 48% to 74%) and 72% (95% CI, 58% to 83%) and specificities of 99% (95% CI, 94% to 100%) and 100% (95% CI, 96% to 100%), respectively, and only the IMT IFA-LANA was included in LCA, together with the IMT IFA-lytic and four enzyme-linked immunosorbent assays (ELISAs). The LCA indicated that the IMT whole-virus ELISA performed best (sensitivity, 87% [95% CI, 81% to 91%]; and specificity, 100% [95% CI, 98% to 100%]), confirming the results obtained with the conventional statistical approach. Commercially available ELISA-based tests yielded the lowest specificities using a spectrum of serum samples. The evaluation of KSHV serological assays is warranted before planning serosurveys in various settings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182752      PMCID: PMC1829101          DOI: 10.1128/JCM.01264-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  37 in total

1.  p53 inhibition by the LANA protein of KSHV protects against cell death.

Authors:  J Friborg; W Kong; M O Hottiger; G J Nabel
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

2.  Identifying human herpesvirus 8 infection: performance characteristics of serologic assays.

Authors:  E A Engels; D Whitby; P B Goebel; A Stossel; D Waters; A Pintus; L Contu; R J Biggar; J J Goedert
Journal:  J Acquir Immune Defic Syndr       Date:  2000-04-01       Impact factor: 3.731

3.  Highly sensitive assay for human herpesvirus 8 antibodies that uses a multiple antigenic peptide derived from open reading frame K8.1.

Authors:  Lee L Lam; Chou-Pong Pau; Sheila C Dollard; Philip E Pellett; Thomas J Spira
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

4.  Detection of human herpesvirus 8 DNA and antibodies to latent nuclear and lytic-phase antigens in serial samples from aids patients with Kaposi's sarcoma.

Authors:  L Camera Pierrotti; L Masami Sumita; W Santos Freire; H Hehl Caiaffa Filho; V A de Souza
Journal:  J Clin Virol       Date:  2000-05       Impact factor: 3.168

5.  Comparison of serologic assays for detection of antibodies against human herpesvirus 8.

Authors:  J L Corchero; E C Mar; T J Spira; P E Pellett; N Inoue
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

6.  HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma.

Authors:  N Dupin; T L Diss; P Kellam; M Tulliez; M Q Du; D Sicard; R A Weiss; P G Isaacson; C Boshoff
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

7.  Kaposi's sarcoma-associated herpesvirus serology in Europe and Uganda: multicentre study with multiple and novel assays.

Authors:  O Schatz; P Monini; R Bugarini; F Neipel; T F Schulz; M Andreoni; P Erb; M Eggers; J Haas; S Buttò; M Lukwiya; J R Bogner; S Yaguboglu; J Sheldon; L Sarmati; F D Goebel; R Hintermaier; G Enders; N Regamey; M Wernli; M Stürzl; G Rezza; B Ensoli
Journal:  J Med Virol       Date:  2001-09       Impact factor: 2.327

8.  Correlates of prevalent and incident Kaposi's sarcoma-associated herpesvirus infection in men who have sex with men.

Authors:  Corey Casper; Anna Wald; John Pauk; Stephen R Tabet; Lawrence Corey; Connie L Celum
Journal:  J Infect Dis       Date:  2002-03-11       Impact factor: 5.226

Review 9.  Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.

Authors:  Lyubomir A Dourmishev; Assen L Dourmishev; Diana Palmeri; Robert A Schwartz; David M Lukac
Journal:  Microbiol Mol Biol Rev       Date:  2003-06       Impact factor: 11.056

Review 10.  Pathogenesis of Kaposi's sarcoma.

Authors:  Darya Bubman; Ethel Cesarman
Journal:  Hematol Oncol Clin North Am       Date:  2003-06       Impact factor: 3.722

View more
  18 in total

1.  Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA.

Authors:  Georgina L Mbisa; Wendell Miley; Christine J Gamache; William K Gillette; Dominic Esposito; Ralph Hopkins; Michael P Busch; George B Schreiber; Richard F Little; Robert Yarchoan; Betty A Ortiz-Conde; Nazzarena Labò; Denise Whitby
Journal:  J Immunol Methods       Date:  2010-03-04       Impact factor: 2.303

2.  Prevalence of viremia and oral shedding of rhesus rhadinovirus and retroperitoneal fibromatosis herpesvirus in large age-structured breeding groups of rhesus macaques (Macaca mulatta).

Authors:  Jessica A White; Patricia A Todd; Joann L Yee; Alexis Kalman-Bowlus; Kelsey S Rodgers; Xiaowei Yang; Scott W Wong; Peter Barry; Nicholas W Lerche
Journal:  Comp Med       Date:  2009-08       Impact factor: 0.982

3.  Development of whole-virus multiplex luminex-based serological assays for diagnosis of infections with kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 homologs in macaques.

Authors:  Jonathan T Ryan; Timothy M Rose
Journal:  Clin Vaccine Immunol       Date:  2013-01-23

4.  Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe.

Authors:  Thomas B Campbell; Margaret Borok; Buxton Ndemera; Suzanne Fiorillo; Irene E White; Xing-quan Zhang; Rhoderick N Machekano; David Katzenstein; Lovemore Gwanzura
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

Review 5.  Comparative pathobiology of Kaposi sarcoma-associated herpesvirus and related primate rhadinoviruses.

Authors:  Susan V Westmoreland; Keith G Mansfield
Journal:  Comp Med       Date:  2008-02       Impact factor: 0.982

6.  Transmission of human herpesvirus type 8 infection within families in american indigenous populations from the Brazilian Amazon.

Authors:  Jaila D Borges; Vanda A U F Souza; Claudia Giambartolomei; Frank Dudbridge; Wilton S Freire; Shinai Arriel Gregório; Pasesa Pascuala Quispe Torrez; Mariana Quiroga; Philippe Mayaud; Claudio S Pannuti; Maria Cláudia Nascimento
Journal:  J Infect Dis       Date:  2012-04-03       Impact factor: 5.226

7.  Variations in human herpesvirus type 8 seroprevalence in Native Americans, South America.

Authors:  Vanda A U F Souza; Francisco M Salzano; Maria Luiza Petzl-Erler; Maria Claudia Nascimento; Philippe Mayaud; Jaila Dias Borges; Claudio S Pannuti
Journal:  Emerg Infect Dis       Date:  2010-06       Impact factor: 6.883

8.  Non-detection of human herpesvirus 8 (HHV-8) DNA in HHV-8-seropositive blood donors from three Brazilian regions.

Authors:  José Eduardo Levi; Maria Claudia Nascimento; Laura Masami Sumita; Vanda Akico Ueda Fick de Souza; Wilton S Freire; Philippe Mayaud; Claudio S Pannuti
Journal:  PLoS One       Date:  2011-08-08       Impact factor: 3.240

9.  Diagnostic performance of various tests and criteria employed in allergic bronchopulmonary aspergillosis: a latent class analysis.

Authors:  Ritesh Agarwal; Dipesh Maskey; Ashutosh Nath Aggarwal; Biman Saikia; Mandeep Garg; Dheeraj Gupta; Arunaloke Chakrabarti
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

10.  Professional antigen presenting cells in human herpesvirus 8 infection.

Authors:  Emilee R Knowlton; Lauren M Lepone; Jun Li; Giovanna Rappocciolo; Frank J Jenkins; Charles R Rinaldo
Journal:  Front Immunol       Date:  2013-01-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.